New Weight-Loss shot shows promise in early trial

NCT ID NCT06118021

Completed Disease control Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tested an investigational drug called HS-20094 in 200 overweight or obese adults. Participants received either the drug or a placebo injection over several weeks. The main goal was to see how much weight they lost and whether the drug was safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20094 injection
What this could lead to: If successful, this could point toward a new medication to help people with obesity lose weight.
What could go wrong: This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. Side effects are possible, and the drug may not prove effective enough for further development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Locations

The Fourth Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 150001, China
the Fourth Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.